

Diabetes Mellitus: Once More About Diagnostics.

Mirzazada V.A., Sultanova S.S., Ismayilova S.M., Huseynova A.R., Aliyeva A.Z., Imamaliyeva U.K.,
Huseynzade N.H., Azadova A.F.

Azerbaijan State Advanced Training Institute for Doctors named after A. Aliyev.

ABSTRACT

Background: Early identification and precise diagnosis of diabetes is crucial. However, determination of diabetes cases leads to psychological, social and economic consequences. Due to this fact, diagnosis of diabetes mellitus should be validated. However, there are some discrepancies in diabetes diagnostics and defining criteria.

Objective: The purpose of this study was to investigate whether the criteria random plasma glucose ≥ 200 mg/dL (≥ 11.1 mmol/L) in the presence of the classic hyperglycemic symptoms “ is reliable and is there need to change this criterion for diagnosis of diabetes mellitus.

Material and Methods: Specificity of diabetes classic symptoms were investigated by literature analysis for identification of these symptoms' frequency in other diseases and conditions. The data of 134 people were analyzed in this study. Venous plasma glucose researched at fasting and 30, 60, 90, and 120 minutes after a 75.0-g glucose load (Precision PCx Medi Sense, Abbot, USA), as well as A1c levels (SDA1c Care, SD Biosensor, Korea). Statistical analysis was performed by using Fischer exact.

Results Diabetes classic symptoms analysis demonstrated their non specificity. Specificity of random plasma glucose ≥ 250 mg/dl was statistically highly significant ($p < 0.00001$) than random plasma glucose ≥ 200 mg/dl: 100% vs 69%.

Conclusion: In the presence of classic hyperglycemia symptoms it is recommended to diagnose diabetes by using random plasma glucose ≥ 250 mg/dl.

Keywords

Random plasma glucose, diabetes mellitus diagnosis, classic hyperglycemia symptoms.

Corresponding Author Information

Valeh Mirzazada

Azerbaijan State Advanced Training Institute for Doctors, Head of the Therapy Department, Azerbaijan, Tel: +99450 2122723.

Received: November 10, 2021; **Accepted:** November 29, 2021; **Published:** December 05, 2021

Copyright: © 2021 ASRJS. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Citation: Mirzazada VA, Sultanova SS, Ismayilova SM, et al. Diabetes Mellitus: Once More About Diagnostics.. Int J Diabetes Metabolic Synd. 2021;1(2):1-5.

Diabetes mellitus (DM) is a widespread disease very often characterized by greater chances of developing severe complications, poor prognosis and significant costs [1]. The disease is still considered incurable, although we are increasingly talking about remission [2,3], and the diagnosis itself has a serious negative impact on the person, family, friends, and others [4].

The criteria for DM diagnostics proposed by various organizations based on [5, 6, 7, 8, 9, 10, 11]:

- fasting glycaemia (FG) ≥ 126 mg/dL or ≥ 7.0 mmol/L;
- glycaemia 2 hours after a 75-g glucose load (G2h) ≥ 200 mg/dL or ≥ 11.1 mmol/L;
- HbA1c levels ($\geq 6.5\%$ or ≥ 48 mmol/mol) are identical.

In guidelines by American Diabetes Association [5], International Diabetes Federation [6], World Health Organization [7], American Association of Clinical Endocrinology [8], Canadian Diabetes Association [9], United Kingdom [10], Australian Diabetes Society [11] there is also a fourth item: the presence of classic hyperglycemic symptoms (or signs of hyperglycemic crisis) jointly with a random plasma glucose (RPG) ≥ 200 mg/dL or ≥ 11.1 mmol/L.

It should be noted that the guidelines by WHO [12, 13], by Diabetes Australia [14] and by Azerbaijan Association of Endocrinology, Diabetology and Therapeutic Education (AAEDTE) [15] do not contain this composite indicator for the diagnosis of DM.

We would like to notify that the document of WHO dated 2019 “World Health Organization Classification of Diabetes Mellitus” [7], indicates that random plasma glucose can be used for patients with classic symptoms of DM. Authors referred to WHO document of 2011 “Use of Glycated Hemoglobin (HbA1c) in the diagnosis of Diabetes Mellitus. Abbreviated Report of a World Health Organization Consultation” in which, however, these recommendations are absent. In addition, authors of WHO 2019 [7], don’t clarify whether changes occurred in official position of WHO regarding the diagnostic criteria for DM.

The purpose of this study was to investigate whether the criteria RPG ≥ 200 mg/dL (≥ 11.1 mmol/L) in the presence of the classic hyperglycemic symptoms “is reliable and is there need to change this criterion for diagnosis of DM.

Materials and methods

The study consisted of three parts.

The task of the first part was to determine how specific to DM symptoms of hyperglycemia which are considered “classic”. In order to answer this question, the frequency of these symptoms in other diseases and conditions was analyzed. The first part of the study involved a review of the literature published in PubMed.

The task of the second part of the study was to analyze the incidence of glycemia levels of 200 mg/dL (11.1 mmol/L) or more in the postprandial state in people with newly diagnosis DM, prediabetes (PD), and normal glucose metabolism (NGM). The results of the

glucose tolerance test were used as a model of the postprandial state.

The task of the third part of the study was to determine the optimal RPG level for the diagnosis of DM in the presence of classic hyperglycemic symptoms.

During the second and third parts of the study, the results of 134 people were analyzed. Six subjects had DM, 41 had PD and 87 had NGM.

The examination determined glucose in venous plasma at fasting and 30, 60, 90, and 120 minutes after a 75.0-g glucose load (Precision PCx Medi Sense, Abbot, USA), as well as A1c levels (SDA1c Care, SD Biosensor, Korea).

Table 1 shows the criteria used to assess the results of the examination.

Table 1: Diagnostic criteria for NGM, DM and PD according to AAEDTE [15].

Parameters	Units	NGM	PD	DM
HbA1c	%	≤ 5.6	5.7-6.4	≥ 6.5
	mmol/mol	≤ 38	39-47	≥ 48
FG	mg/dl	<110	110 - 125	≥ 126
	mmol/l	<6.1	6.1 - 6.9	≥ 7.0
G2h	mg/dl	≤ 139	140 - 199	≥ 200
	mmol/l	≤ 7.7	7.8 - 11.0	≥ 11.1

Statistical analysis was performed by the Fisher exact method [16].

Results

The symptoms of DM are well known. The typical symptoms of DM include excessive thirst, blurred vision, bedwetting, frequent urination, lack of energy and fatigue, constant hunger and sudden weight loss [17]. However, it is important to be aware that symptoms of DM are not specific and may occur in other diseases as well [18-37]. Excessive thirst may occur in diabetes insipidus [18,19], hyponatremia [20], chronic hemodialysis [21], chronic heart failure [22] and schizophrenia [23]. Blurred vision symptom may occur in range of eye diseases [24]. Bedwetting may occur in range of urological diseases such as monosymptomatic nocturnal enuresis [25], pelvic floor disorders in women [26], urinary incontinence in men [27]. Lack of energy, fatigue may occur in some neurological disease [28], chronic liver disease [29], cancer [30] and as well as in depression [31]. Another symptom of DM such as constant hunger may occur in monogenic obesity and congenital generalized lipodystrophy [32], hyperthyroidism [33] or in anxiety [34]. Sudden weight loss also can happen after a stressful event, although it can be a sign of a serious illness such as hyperthyroidism [35], cancer [36] and depression [37].

Table 2 shows the frequency of glucose levels ≥ 200 mg/dL (≥ 11.1 mmol/mol) for NGM, PD and type 2 DM.

Table 2: The frequency of glucose levels ≥ 200 mg/dL ($\geq 11,1$ mmol/mol) for NGM, PD and DM type 2.

State of glucose metabolism	Total number of subjects	Subjects with glucose values ≥ 200 mg/dL	
		n	%
NGM	87	27	31.0
PD	41	30	73.2
DM	6	6	100

Those with DM had glucose level ≥ 200 mg/dl in 100% of cases. In PD glucose level 200 mg/dl and above had place in 73% of cases. In NGM 31% of subjects had discussable levels of plasma glucose. Hence, 57 subjects of total 128 investigated without DM (44.5%) had results ≥ 200 mg/dl (11,1 mmol/l).

Definition of specificity of given criteria [38] indicates that:

$$\text{Specificity} = \frac{\text{true negative}}{\text{total number of well individual in population}} = 100 * \frac{60}{87} = 69.0\%$$

Table 3 shows the frequency of glucose levels ≥ 250 mg/dL ($\geq 11,1$ mmol/mol) for NGM, PD and DM type 2.

Table 3: The frequency of glucose levels ≥ 250 mg/dL ($\geq 11,1$ mmol/mol) for NGM, PD and DM type 2.

State of glucose metabolism	Total number of subjects	Subjects with glucose values ≥ 250 mg/dL	
		n	%
NGM	87	0	0
PD	41	0	0
DM	6	2	33.3

Those with DM had glucose level ≥ 250 mg/dl in 100% of cases. In cases with NGM and PD glucose values ≥ 250 mg/dL were absent.

Definition of specificity of given criteria [38] indicates that:

$$\text{Specificity} = 100 * \frac{87}{87} = 100.0\%$$

Diabetes classic symptoms analysis demonstrated their non specificity. Specificity of random plasma glucose ≥ 250 mg/dl was statistically highly significant ($p < 0.00001$) than random plasma glucose ≥ 200 mg/dl: 100% vs 69%.

Discussion

Establishing of DM diagnosis leads to serious psychological, social and economic consequences [5,7,13,17]. Our study showed that classic symptoms of DM may occur in range of other diseases and conditions. Perhaps, specificity of symptoms is not high. Maybe, specificity will increase with presence of symptoms combination, but it wasn't proved by any of current research. Moreover, indication for symptom combination variants is absent in all presence guidelines [5-11,14,15].

Necessity of strict approach to DM diagnostics is reflected in all existing DM recommendations. Three diagnostic tests for DM are currently recommended, including measurement of fasting plasma glucose, 2-hour (2-h) post-load plasma glucose after a 75 g oral glucose tolerance test (OGTT) and HbA1c [5]. DM diagnosis requires presence of [5-11,14,15]:

1. 2 criteria out of 3 (FG ≥ 126 mg/dl; G2h ≥ 200 mg/dl; HbA1c $\geq 6.5\%$)
2. Two diabetic criteria out of three diagnostic values for anyone.

According to the results of our study, specificity of random glucose levels ≥ 200 mg/dl (11.1 mmol/l) was 69.0%. Considering non-specificity of classic symptoms of DM and taking into account that specificity of symptoms combination is unknown, it is crucial to use the maximal specific glucose parameter. Thus, demonstrated before, specificity of RPG ≥ 200 mg/dl cannot be sufficient. As limitation of our study, we could suggest the use of oral glucose tolerant test instead of glucose monitoring for 24 hours. However, in our opinion, glucose load tests similar to 75 gr glucose tolerant test continue to exist in real clinical setting. Due to the fact that, glucose level of 250 mg/dl didn't occur in subjects with NGM and PD in other words, had 100% specificity, we consider namely this level of glucose as appropriate diagnostic test. Glucose levels ≥ 250 mg/dl the same value that is associated with possibility of occurrence diabetic ketoacidosis [39]. Higher values are characterized with hyperosmolar state [40]. This level of glucose also is one of the fundamental values for assessment 24-hour glucose monitoring [41].

Therefore, in our opinion, diagnostic criteria for diabetes mellitus should be as follows:

1. FG ≥ 126 mg/dl
2. G2h ≥ 200 mg/dl
3. HbA1C $\geq 6.5\%$
4. In presence of classic symptoms of hyperglycemia RPG ≥ 250 mg/dl.

References:

1. International Diabetes Federation. IDF Diabetes Atlas. Ninth edition 2019. Diabetes Research and Clinical Practice, 2019; 157: 107841. <https://doi.org/10.1016/j.diabres.2019.107841>.
2. Matthew C Riddle, William T Cefalu, Philip H Evans et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. The Journal of clinical endocrinology and metabolism. 2021; dgab585. doi:10.1210/clinem/dgab585.
3. Naseer Ahmad Bhat, Krishna Prasad Muliya, Santosh Kumar Chaturvedi. Clinical case of type 2 diabetes remission. Georgian Medical News. 2018; 4 (277): 35-39.
4. Bhat, Naseer A et al. Psychological Aspects of Diabetes. EMJ Diabet. 2020; 8[1]: 90-98. <https://doi.org/10.33590/emjdiabet/20-00174>.
5. American Diabetes Association Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021; 44(Supplement 1): S15-S33. <https://doi.org/10.2337/dc21-S002>.

6. Amanda Adler, Cliff Bailey, Juliana CN Chan, et al. IDF Clinical Practice Recommendations for managing Type 2 Diabetes in Primary Care. International Diabetes Federation. 2017; 11.
7. Classification of Diabetes Mellitus 2019, WHO 2019; 8. <https://www.who.int/publications/i/item/classification-of-diabetes-mellitus>.
8. Yehuda Handelsman, Zachary T Bloomgarden, George Grunberger, et al. American association of clinical endocrinologists and American college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. *Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*. 2015; 21 Suppl 1(Suppl 1):1-87. Doi: 10.4158/EP15672.GL.
9. Diabetes Canada Clinical Practice Guidelines Expert Committee et al. Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. *Canadian journal of diabetes*. 2018; 42 Suppl 1: S10-S15. Doi: 10.1016/j.cjcd.2017.10.003.
10. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. National Institute for Health and Care Excellence Guideline. 2015 Aug.
11. Australian Diabetes Society, Recommendations for the Use of HbA1c for Diagnosis of Diabetes. *Med J Aust*. 2012;197(4):220-221. Doi: 10.5694/mja12.10988.
12. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Report of a WHO/IDF Consultation. World Health Organization 2006. <https://apps.who.int/iris/handle/10665/43588>.
13. Global report on diabetes. World Health Organization 2016. <https://www.who.int/publications/i/item/9789241565257>.
14. National Evidence Based Guideline for Case Detection and Diagnosis of Type 2 Diabetes. The Boden Institute of Obesity, Nutrition and Exercise the University of Sydney. 2009. <https://www.diabetesaustralia.com.au/wp-content/uploads/National-Evidence-Based-Guideline-for-Case-Detection-and-Diagnosis-of-Type-2-Diabetes.pdf>.
15. Mirzazade, Valeh et al. Standards of diagnosis diabetes mellitus and prediabetes. Invitation to discussion. Azerbaijan Association of Endocrinology Diabetology and Therapeutic Education. 2021.
16. Easy Fisher Exact Test Calculator. Social Science Statistics <https://www.socscistatistics.com/tests/fisher/default2.aspx>
17. Diabetes Atlas 9th edition, International Diabetes Federation 2019. <https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/159-idf-diabetes-atlas-ninth-edition-2019.html>.
18. Mirjam Christ-Crain, Daniel G. Bichet, Wiebke K. Fenske, et al. Diabetes insipidus. *Nature reviews. Disease primers*. 2019; 5: 54. doi:10.1038/s41572-019-0103-2.
19. Nicole Nigro, Mathis Grossmann, Cherie Chiang, et al. Polyuria-polydipsia syndrome: a diagnostic challenge. *Internal medicine journal*. 2018; 48(3): 244-253. <http://dx.doi.org/10.1111/imj.13627>.
20. Joseph G Verbalis, Steven R Goldsmith, Arthur Greenberg, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. *The American journal of medicine*. 2013; 126(10 Suppl 1): S1-42. Doi:10.1016/j.amjmed.2013.07.006.
21. Bossola M, Calvani R, Marzetti E, Picca A, et al. Thirst in patients on chronic hemodialysis: What do we know so far?. *International urology and nephrology*. 2020; 52,4 : 697-711. DOI: 10.1007/s11255-020-02401-5.
22. Sabine M Allida, Sally C Inglis, Patricia M Davidson, et al. Thirst in chronic heart failure: a review. *Journal of clinical nursing*. 2015; 24(7-8): 916-926. DOI: 10.1111/jocn.12732.
23. M J McKinley, M J Cairns, D A Denton, et al. Physiological and pathophysiological influences on thirst. *Physiology & behavior*. 2004; 81(5): 795-803. DOI: 10.1016/j.physbeh.2004.04.055.
24. Preventing Diabetes Problems. Diabetic Eye Disease. National Institute of Diabetes and Digestive and Kidney Disease 2017. <https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-eye-disease>.
25. Guy Bogaert, Raimund Stein, Shabnam Undre, et al. Practical recommendations of the EAU-ESPU guidelines committee for monosymptomatic enuresis-Bedwetting. *Neurourology and urodynamics*. 2020; 39(2): 489-497. DOI: 10.1002/nau.24239.
26. Jennifer M Wu, Camille P Vaughan, Patricia S Goode, et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. *Obstetrics and gynecology*. 2014; 123(1): 141-148. DOI: 10.1097/AOG.000000000000057.
27. Eric Chung, Darren J Katz, Christopher Love. Adult male stress and urge urinary incontinence - A review of pathophysiology and treatment strategies for voiding dysfunction in men. *Australian family physician*. 2017; 46(9): 661-666.
28. Penner, Iris-Katharina, and Friedemann Paul. Fatigue as a symptom or comorbidity of neurological diseases. *Nature reviews Neurology*. 2017; vol. 13(11): 662-675. Doi:10.1038/nrneuro.2017.117.
29. Lynn H Gerber, Ali A Weinstein, Rohini Mehta, et al. Importance of fatigue and its measurement in chronic liver disease. *World journal of gastroenterology*. 2019; 25(28): 3669-3683. Doi: 10.3748/wjg.v25.i28.3669.
30. Ann M. Berger, Kathi Mooney, Amy Alvarez-Perez, et al. Cancer-Related Fatigue, Version 2.2015. *Journal of the National Comprehensive Cancer Network: JNCCN*. 2015; 13(8): 1012-1039. DOI:10.6004/jnccn.2015.0122.
31. Elizabeth C Corfield, Nicholas G Martin, and Dale R Nyholt. Co-occurrence and symptomatology of fatigue and depression. *Comprehensive psychiatry*. 2016; 71: 1-10. DOI: 10.1016/j.comppsy.2016.08.004.
32. Santos, José L, and Víctor A Cortés. Eating behaviour in contrasting adiposity phenotypes: Monogenic obesity and congenital generalized lipodystrophy. *Obesity reviews: an official journal of the International Association for the Study of Obesity*. 2021; 22(1): e13114. DOI: 10.1111/obr.13114.

-
33. Sven Röjdmarm, Jan Calissendorff, Olle Danielsson, et al. Hunger-satiety signals in patients with Graves' thyrotoxicosis before, during, and after long-term pharmacological treatment. *Endocrine*. 2005; 27(1): 55-61. DOI: 10.1385/ENDO:27:1:055.
 34. Morris, A. Anxiety-induced weight loss. *Nat Rev Endocrinol*. 2019; 15(3):130. DOI: 10.1038/s41574-019-0169-7.
 35. George J Kahaly, Luigi Bartalena, Lazlo Hegedüs, et al. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. *European thyroid journal*. 2018; 7(4):167-186. DOI: 10.1159/000490384.
 36. Kenneth Fearon, Florian Strasser, Stefan D Anker, et al. Definition and classification of cancer cachexia: an international consensus. *The Lancet Oncology*. 2011 May;12(5):489-95. DOI: 10.1016/S1470-2045(10)70218-7.
 37. F Rice, L Riglin, T Lomax, et al. Adolescent and adult differences in major depression symptom profiles. *Journal of affective disorders*. 2019; 243:175-181. DOI: 10.1016/j.jad.2018.09.015.
 38. Swift, Amelia et al. What are sensitivity and specificity? *Evidence-Based Nursing*. 2020; 23(1):2-4. DOI: 10.1136/ebnurs-2019-103225.
 39. Dhatariya, K.K., Glaser, N.S., Codner, E. et al. Diabetic Ketoacidosis. *Nat Rev Dis Primers* 2020; 6(1):40. DOI: <https://doi.org/10.1038/s41572-020-0165-1>.
 40. Milanesi A, Weinreb JE. Hyperglycemic Hyperosmolar State. [Updated 2018 Aug 1]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc.
 41. Reddy, Nihaal, et al. "Monitoring Technologies- Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control." *Endotext*, edited by Kenneth R Feingold, Editor-in-chief, Bradley Anawalt, et. al., MDText.com, Inc., 16 August 2020.